These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8222256)

  • 1. The FDA's perspective on the evaluation of tumor marker tests.
    Aziz KJ; Maxim PE
    Clin Chem; 1993 Nov; 39(11 Pt 2):2439-43. PubMed ID: 8222256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour markers: current status and future applications.
    Aziz K
    Scand J Clin Lab Invest Suppl; 1995; 221():153-5. PubMed ID: 7652488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
    Aziz KJ; Sliva CA; Gutman SI
    Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
    [No Abstract]   [Full Text] [Related]  

  • 4. Food and Drug Administration (FDA)'s impact on laboratory performance: FDA's perspective.
    Gutman S
    Clin Chem; 1996 May; 42(5):786-9. PubMed ID: 8653915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical applications of serum tumor markers.
    Bates SE
    Ann Intern Med; 1991 Oct; 115(8):623-38. PubMed ID: 1716430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy in clinical chemistry--does anybody care?
    Tietz NW
    Clin Chem; 1994 Jun; 40(6):859-61. PubMed ID: 8087978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical device labeling and advertising: an overview.
    Basile EM; Armentrout E; Reeves KN
    Food Drug Law J; 1999; 54(4):519-33. PubMed ID: 11824451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Jay Crowley the FDA's perspective on the unique device identification system.
    Crowley J
    Healthc Financ Manage; 2009 Sep; 63(9):48-51. PubMed ID: 19743648
    [No Abstract]   [Full Text] [Related]  

  • 9. Approval of novel biomarkers: FDA's perspective and major requests.
    Scherf U; Becker R; Chan M; Hojvat S
    Scand J Clin Lab Invest Suppl; 2010; 242():96-102. PubMed ID: 20515286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An FDA clinical instrument "recall".
    Alpert NL
    Clin Chem; 1975 May; 21(6):782-5. PubMed ID: 1122628
    [No Abstract]   [Full Text] [Related]  

  • 12. Performance characteristics for an immunoassay.
    Vadlamudi SK; Stewart WD; Fugate KJ; Tsakeris TM
    Scand J Clin Lab Invest Suppl; 1991; 205():134-8. PubMed ID: 1947743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is FDA's medical device evaluation process overly complaisant to industry?
    Margolis RE
    Healthspan; 1992; 9(7):19-20. PubMed ID: 10121440
    [No Abstract]   [Full Text] [Related]  

  • 14. Using the FDA's Device Experience Network.
    Collins JL
    Oncol Nurs Forum; 1992 Apr; 19(3):524. PubMed ID: 1594477
    [No Abstract]   [Full Text] [Related]  

  • 15. Medical devices; clinical chemistry and clinical toxicology devices; classification of newborn screening test systems for amino acids, free carnitine, and acylcarnitines using tandem mass spectrometry. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68254-5. PubMed ID: 15562554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA's medical device standards policy.
    Stimson RA
    J Parenter Sci Technol; 1981; 35(2):60-2. PubMed ID: 7229834
    [No Abstract]   [Full Text] [Related]  

  • 17. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA's humanitarian device exemption program.
    Eydelman MB; Chen EA
    Health Aff (Millwood); 2011 Jun; 30(6):1210-2; author reply 1212. PubMed ID: 21653975
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's revitalization of medical device review and regulation.
    Kessler DA
    Biomed Instrum Technol; 1994; 28(3):220-6. PubMed ID: 8061717
    [No Abstract]   [Full Text] [Related]  

  • 20. Medical devices; exemptions from premarket notification; class II devices--FDA, Final rule.
    Fed Regist; 1998 Nov; 63(212):59222-31. PubMed ID: 10187384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.